Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.57 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.57 |
| ▸ | PDE5A | O76074 | 16/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL427311 | 0.99 | ADORA3 (0.63) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Sulfuric Acid SCHEMBL428371 | 0.97 | ADORA3 (0.61) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Phosphoric Acid SCHEMBL430663 | 0.97 | ADORA3 (0.61) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL431126 | 0.96 | ADORA3 (0.62) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Maleic Acid SCHEMBL427303 | 0.96 | ADORA3 (0.60) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Fumaric Acid SCHEMBL427304 | 0.96 | ADORA3 (0.60) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Nitric Acid SCHEMBL429168 | 0.95 | ADORA3 (0.59) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Nitric Acid SCHEMBL429167 | 0.95 | ADORA3 (0.59) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL430662 | 0.94 | ADORA3 (0.58) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL10083045 | 0.91 | KCNH2 (0.79) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790546-B1 | NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | BAYER AG (DE) | 2024-08-21 | — | — | EP | claimed |
| EP-3525779-B1 | COMBINATION CONTAINING THE SGC STIMULATOR VERICUGUAT AND THE MINERALCORTICOID RECEPTOR ANTAGONIST FINERENONE | Bayer Pharma AG (DE) | 2024-06-05 | — | — | EP | claimed |
| US-20210052528-A1 | THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-25 | — | — | US | claimed |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2020-12-24 | — | — | US | claimed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | claimed |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-23 | — | — | US | claimed |
| US-20180263981-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2018-09-20 | — | — | US | claimed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | claimed |
| US-9993476-B2 | Substituted 5-flouro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2018-06-12 | — | — | US | claimed |
| EP-3291811-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | claimed |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELl SCHAFT (DE) | 2016-06-09 | — | — | US | claimed |
| EP-3024455-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-01 | — | — | EP | claimed |
| US-9266885-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2016-02-23 | — | — | US | claimed |
| EP-2576547-B1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | ADVERIO PHARMA GMBH (DE) | 2016-01-27 | — | — | EP | claimed |
| US-20150080414-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | claimed |
| WO-2015011086-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-29 | — | — | WO | claimed |
| US-8921377-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-30 | — | — | US | claimed |
| US-20130237551-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-12 | — | — | US | claimed |
| US-8420656-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | claimed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | PDE5A, PDE2A, PDE3A | ADORA3 3072/4885KCNH2 2945/4885GUCY1A1 11/4885 |
| US-20180263981-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885GUCY1A1 1337/4885 |
| US-20150080414-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885GUCY1A1 1337/4885 |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885GUCY1A1 1337/4885 |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | PDE5A, PDE3A, GMPS | ADORA3 1527/4885KCNH2 1661/4885GUCY1A1 7/4885 |
| US-20210052528-A1 | THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | GUCY1A2, GUCY1A1, PRKG1 | ADORA3 1349/4885KCNH2 2540/4885GUCY1A1 2/4885 |
| US-20130237551-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885GUCY1A1 1337/4885 |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | PDE5A, GMPS, PDE3A | ADORA3 1351/4885KCNH2 1467/4885GUCY1A1 9/4885 |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885GUCY1A1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.